Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Evaluation parameter</td><td class="align_center">CA19-9</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Sensitivity</td><td class="align_center">85.7%</td></tr><tr><td class="align_left">Specificity</td><td class="align_center">94.1%</td></tr><tr><td class="align_left">Positive predictive value</td><td class="align_center">6/7 (85.7%)</td></tr><tr><td class="align_left">Negative predictive value</td><td class="align_center">17/18 (94.4%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>HPD: hyperprogressive disease.<br/></div></td></tr></table>

<div>Positive predictive value and negative predictive value of HPD in patients with pancreatic cancer with immunotherapy according to CA199 test when the cut-off value is 167%.</div>

Disease Markers

tab5

Table 5

Table 5: Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer 